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SYNTHESIS OF DOXORUBICIN-BASED PRODRUG AND ACTIVATABLE MR
NANOPROBE FOR THE IMAGING AND TREATMENT OF CANCER

An Abstract of the Thesis by
Bayan Ahmad S Dous

Magnetic Resonance Imaging (MRI) is increasingly being used as a diagnostic
tool for cancer. We propose a novel molecular probe, Gadolinium-DTPA
disulfide-bonded Doxorubicin (Gd-DTPA-SS-Doxo) encapsulated in iron oxide
which could provide a dual modality for detecting malignant growth while
simultaneously targeting treatment options. We first synthesized Gd-DTPA-SSDoxo followed by encapsulation within the poly (acrylic acid) (PAA) coating of
iron oxide nanoparticle (IONP), producing a nanoprobe (IO-Gd-DTPA-SS-Doxo)
with quenched longitudinal spin lattice magnetic relaxation (T1). After receptormediated internalization, Gd-DTPA-SS-Doxo is released from the nanoprobe’s
polymeric coating due to the acidic microenvironment of the tumor. When the
molecular probe is subjected to various enzymes present in the cancerous cells,
the disulfide bond of the molecular probe is cleaved. This results in an
intracellular release of Gd-DTPA complex and Doxo with subsequent T1
activation and cytotoxic effect respectively. Therefore, the proposed framework
would give dual mode MR imaging of malignant growth, target ability and
treatment for disease.
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CHAPTER I

SYNTHESIS OF DOXORUBICIN-BASED PRODRUG AND ACTIVATABLE MR
NANOPROBE FOR THE IMAGING AND TREATMENT OF CANCER

INTRODUCTION
Cancer is presently the second most basic reason for death in the U.S.
As indicated by the American Cancer Society1 prostate cancer is anticipated to
cause roughly 12 million deaths by 2030 1, 164,690 new cases are expected in
2018, and 29,430 estimated deaths. Because of those huge numbers, scientists
are focusing their studies trying to find a way to fight this disease. Currently
practiced techniques such as radiation, surgery, hormone therapy, and
chemotherapy are known to cause harm and damage to the healthy cells, risking
the patients’ survival 2. For this reason; in 1980s, as an attempt to decrease the
damage to healthy cells, scientists worked with nanoparticles (NPs), which were
designed to target only the cancer cells 2. Considering the severity of prostate
cancer, this work will focus on the development of magnetic nanotheranostics for
the imaging and treatment of this cancer.
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Magnetic Resonance Imaging (MRI) is a technique employed in tissue
imaging and clinical diagnosis of diseases. It permits visualization of tissues and
organs, and also makes it possible to regenerate noninvasive sectional images 3.
In other words, molecular imaging techniques facilitate pathologic biomarker
detection, thus, enhancing diagnosis of diseases and improved therapeutic
management 3, 4, 6. MRI has gained significant attention in the field of molecular
imaging due to its numerous benefits, including short imaging times, high spatial
resolution (µm-scale), impressive signal-to-noise (S/N) ratio, and its noninvasive
characteristics 6. Biological processes, such as accumulation of lipids and
angiogenesis signal the early development of some clinical conditions, are widely
targeted by MRI contrast agents 4. In addition, MRI contrast agents target
conditions, such as plaque rupture-induced tissue factors and fibrins; bio
signatures that occur later. These contrast agents combine the benefits of
therapeutic intervention and disease diagnosis since they can be used as
vehicles for drug delivery 6. MRI contrast agents are essential requisites in
distinguishing healthy tissues from infected ones. Water is the primary
constituent of living tissues; MRI primarily targets protons in the water by exciting
and detecting any changes in their rotational motion and direction 7.
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Figure 1: Leading Sites of New Cancer Cases and Deaths – 2018 Estimates1.
In practice, the water content in the tissues and the longitudinal rate of
relaxation, R1 (in terms of 1/sec.), are proportional to the MRI signal; R1 describes
the relaxation rate of the MRI signal during pulse sequencing 4. The protons in
the body tissues are realigned with the magnetic field. An MRI scan stimulates
the protons, which shift from equilibrium. From this excited state there are two
forms of relaxation. The most rapid form of relaxation is the dephasing of the
spins, this is known as T2 relaxation or transverse relaxation. This has the effect
of reducing the overall magnetization vector in the XY plane. The second slower
form of relaxation involves the return to equilibrium of spin up and spin down
states, this is known as T1 relaxation or longitudinal relaxation. This has the
3

effect of restoring the overall magnetization vector in the Z direction. Such
magnetic features make it possible to differentiate tissues 8.
The polymer-coated iron oxide nanoparticles (IONPs) are polymer-coated
and superparamagnetic, which are used to enhance the contrast of tomographic
MR images from disease site and organs. The polymeric coating enhances the
stability of IONPs in aqueous media9. IONPs decrease the MR signal (dark,
negative contrast) of an MRI sequence that is T 2-weighted, by reducing the
transverse time of relaxation time T2 of the neighboring protons 11. So far, IONPs
have proven to be the most desirable superparamagnetic agents in improving the
contrast in T2 MR Scans. The choice of IONPs is often acknowledged by their
minimal toxicity to cancer cells 5.
Gadolinium complex (Gd-DTPA) is a paramagnetic metal chelate used as
a MRI contrast agent. Its principle role is to reduce the water protons’ longitudinal
time of relaxation, T1, thus enhancing the intensity of T1-weighted images (bright,
positive contrast), which can be visualized by a radiologist

12.

Gd-DTPA contrast

agent comprises atoms and molecules that are closely-packed by strong
chemical bonds between the chelating agent (DTPA) and Gd 3+. Due to the high
toxicity of Gd3+, the ions are often coupled with a chelating agent ensuring the
magnetic property is retained. During a MRI scan, the contrast agent is injected
into a tissue and subsequently removed from the human body through the
kidneys.
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The formulation of Gd-DTPA (diethylenetriamine pentaacetic acid) is
essentially an activatable MRI nanoprobe encapsulated within an IONP to obtain
a composite nanoprobe. In nanomedicine, both MRI contrast agents can be
utilized in dual mode, as Gd-IONP. When exposed to acidic environments, the
composite contrast agent is activated, thus, enhancing the T 1 weighted signal
(brighter contrast). The Fe2O3 core comprises magnetically-ordered pairs of Fe2+
and Fe3+ ions within the nanocrystal 9. The net magnetic moment exerted by the
combination exceeds that of the single paramagnetic Gd 3+, Fe2+ and Fe3+. In
tandem, it is expected that the magnetic core will become susceptible to the
intense magnetic moment created and subsequently, affect Gd-DTPA’s time of
relaxation, T1. Further, it is expected that the composite magnetic nanoprobe will
relax at a rate of 1/T1 when the Gd-DTPA complex is extracted from the
polymeric coating of the nanoprobe to elicit dequenching 9.
Many studies have been conducted over time and in one study (Scheme
1) they reported a synthesis of an activatable prodrug (Doxo-SS-Fol), and also a
nonactivatable probe (Doxo-CC-Fol) 13. They observed that due to a high GSH
level in cancer cells the disulfide bond was cleaved leading to the activation of
fluorescence emission and cytotoxicity. On the other hand, it remains OFF when
a non-activatable drug was introduced because of the absence of the cleaving
mechanism.

5

Scheme 1: Doxorubicin-based activatable prodrug for the targeted treatment of
lung cancer13.
To track the final localization of the prodrug cells, the presence of the
folate receptor and the final localization of the conjugate in cultured cells, many
folate conjugation with nanoparticles and fluorescent dyes have been developed
and used 13. In (Scheme 1B), it was found that when the prodrug is linked with
carbon-carbon covalent bond; the fluorescence and cytotoxicity of the
6

doxorubicin are quenched (OFF). on the other hand, it became activated (ON)
when the linkage is done with a disulfide bond (S-S), dithiobis (succinimidyl
propionate) (DSP) were in the design of the conjugation (Scheme 1A); linking
the cytotoxic doxorubicin and the targeting folate unit. So, upon interaction and
by using a specific enzyme associated with disease, an activatable molecular
imaging agent becomes activated; an increase was noticed in its signal output14.
This allows the lower signal background and the image resolution to increase. In
the meantime, when the prodrug is less toxic it enters the sick cells and became
active 13. In this study, the folic acid can act as both a quencher for the
doxorubicin and a receptor targeting ligand (Scheme 1).
In the study15, they designed the prodrug Lac-SS-DCM created with a
disulﬁde bond unit and an alkyne reaction group. It reduces the side effects and
gives higher anticancer effectiveness as well as excellent target ability. The
multivalent galectin-targeting ligand was performed when lactose-mediated
endocytosis resulting from the surface lactose corona15. The quenching of the
strong NIR ﬂuorescence light of the compound Lac-SS-DCM was done via the
newly formed amide bond. In addition, taking advantage of the disulfide bond (SS-) the prodrug causes disband by the enzyme (GSH), which makes the drug to
be active inside the cancer cells15 (Scheme 2).
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Scheme 2: Prodrug Lac-SS-DCM15 for the treatment of cancer.
In a different study16, they provide a design with multimodal probe which
was very active tool for repaid and giving the imaging of the biological steps. This
special design can show multiplex imaging signals due to the interaction with the
specific molecules in the design. They studied and reported that the design
follows a stimuli-responsive disassembly approach and has three sides as shown
in (Scheme 3).
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Scheme 3: The concept behind the design of an activatable probe16.
Santra e t. al., developed novel activatable MR probe by encapsulating
Gd-DTPA complex in iron oxide nanoparticles (IONPs) for the imaging and
treatment of cancer5. It was found that the Gd’s T1 MR contrast was dequenched
(activated) after releasing the Gd-DTPA complex inside the cancer cells,
facilitating for an activatable T1 MR images for diagnosis5.

Scheme 4: composite magnetic nanoprobe IO-PAA-Gd-DTPA and
corresponding T1 MR Activation5.
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The aim of this study is to utilize the Gd-DTPA and IONPs (Fe2+ + F3+)
carrier molecules as a dual mode MRI nanoprobe for treatment and imaging of
cancer. In this study (Scheme 5A), we are proposing a Doxo-SS-Gd-DTPA
nanoprobe encapsulating IONPs for the MR imaging and treatment of cancer.
We hypothesized that the disulfide bond of Doxo-SS-Gd-DTPA will be cleaved by
GSH enzyme, when it enters into the cancer cells. After cleavage, Doxo and GdDTPA will be released, where Doxo will lead to killing the cells and Gd-DTPA will
act as T1 MR bright contrast. Along with the contrast and anticancer property, we
introduced folate surface functionality, which would help in specifically targeting
cancer cells. Further, the probe will remain inactive (prodrug) when it is in the
blood stream because the level of the GSH is lower (1-10 μM) in the blood
stream; and it is high in the cancer cells (1-10 mM) So, the same probe in the
cancer cells get cleaves and releases the Doxo and Gd-DTPA (Scheme 5B).
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Scheme 5: (A) The representation of the proposed activatable MR nanoprobeprodrug. (B) Schematic diagram of the mechanism of action T1 and T2 MR
activation, and pro-drug activation.
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CHAPTER II

RESULT AND DISCUSSION

In this study, we introduced a new cleavable Doxo-SS-Gd-DTPA prodrug; which
will be used as a therapeutic agent in conjunction with T1 and T2 imaging for
cancer. This prodrug will be encapsulated within PAA polymer coating of IONPFol, a typical T2 agent. This would result in the quenching of gadolinium’s T1
signal due to the proximity of iron oxide. The folate on the surface of IONP helps
in recognition of the cancer cells from the healthy cells because most of the
cancer cells overexpress folate receptors. Thereby, the prodrug is targeted to the
tumor site. However, upon target recognition, the PAA coating will be disrupted
by the tumor’s low pH microenvironment, followed by the prodrug Doxo-SS-Gd
release. In addition, the released prodrug will be exposed to higher GSH level in
the cytosol, which will cleave Doxo and Gd-DTPA complex from the Doxo-SSGd-DTPA prodrug. This would lead to an enhanced toxicity from Doxo and
activatable T1 MR signal from the Gd-DTPA complex. Hence, the proposed
system would provide dual-mode MR imaging of cancer, targetability as well
treatment for cancer.
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Synthesis of DOXO-SS-Gd-DTPA: Doxorubicin and Gadolinium in the DoxoSS-Gd-DTPA complex is useful for treatment and imaging, respectively.
Magnetic resonance imaging (MRI) technology is often implemented in the
clinical diagnosis of illnesses and animal imaging 8.

Scheme 6: The synthesis and the mechanism of the activatable prodrug.

The Gd-DTPA complex was synthesized using reported protocol8 prior to the
molecular probe synthesis (Doxo-SS-Gd-DTPA), and dissolved in water. T1 and
T2 MR values were measured and dilution was carried out until desired T1 and
T2 values were achieved. Furthermore, Doxo was conjugated to Gd-DTPA
complex using DSP cross-linker. The NH2 group on Gd-DTPA complex and Doxo
13

gets attached to the DSP linker in presence of Et3N in order to synthesize
activatable Doxo-SS-Gd-DTPA complex in solution (Scheme 6). When this probe
will enter the cancer cells the S-S bond will break due to a high level of
glutathione in cancer cells. This solution was further characterized and then
encapsulated in IONP.
Characterization of Doxo-SS-Gd-DTPA: After preparation of Doxo-SS-GdDTPA solution, the absorbance and fluorescence intensity were measured for
detecting the presence of Doxo. An absorbance peak for the free Doxo and free
molecular Doxo-SS-Gd-DTPA probe was detected at 495 nm (Figure A).
Although there was a slight decrease in the intensity of free molecular probe, the
absorbance wavelength was similar to that of free Doxo. After measuring the
absorbance, the fluorescence intensity was also measured for both free Doxo
and free molecular probe which was at 595 nm (Figure B). Again, there was a
slight decrease in the intensity of free molecular probe because Doxo is
complexed with Gd-DTPA.
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Moving forward, T1 and T2 values were taken for the same sample; T1 value
was measured to be 53.43 ms (Figure C) which is a very strong signal for T1,
whereas T2 was 700 ms (Figure D) indicative of the weak T2 MR property of the
molecular probe.

Figure 2: (A) Comparison between free Doxo and the molecular probe UV.
(B) Comparison between free Doxo and the molecular probe fluorescence.
(C), (D) MR Data of molecular probe before encapsulation.
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Synthesis of iron oxide nanoparticles (IONP): Iron oxide nanoparticles
(IONP) has attracted large interest due to their superparamagnetic property.
Some common uses of synthesized nanoparticles include high-sensitivity
bimolecular MRI, catalysis, superparamagnetic relaxometry (SPMR), and
sensors20. Herein, we formulated iron oxide nanoparticle using solvent
precipitation method. For performing the synthesis of IONP, three different
solutions of i) iron salts solution, ii) poly acrylic acid (PAA) solution, and iii)
ammonium hydroxide (NH4OH) solution were prepared. First, the iron salts
solution was added to NH4OH solution with constant mixing using vortex, and
then PAA solution was added to stabilize the iron oxide nanoparticles. After
carrying out the entire reaction, the resultant IONP solution was centrifuged to
bring it to the desired size. Further, the solution was purified using dialysis
technique and characterized using DLS (dynamic light scattering).

Molecular and nano prodrug

T1 (ms)

T2 (ms)

Doxo-SS-Gd

53.43

700

Doxo-SS-Gd-DTPA-IONP

139

79

Table 1: Molecular probe before encapsulation MR Data and Nanoprobe after
encapsulation MR Data.

16

Figure 3: (A) After encapsulation UV for Doxo-SS-Gd-DTPA-IONPs. (B) After
encapsulation fluorescence for Doxo-SS-Gd-DTPA-IONPs. (C), (D) Nanoprobe
after encapsulation MR Data.
The synthesized Doxo-S-S-Gd-DTPA was also characterized using Bruker’s
Microflex MALDI-TOF spectrometer using dihydrobenzoic acid as matrix. A
detected a peak at 1210 Da, which corresponds to the (M-5H) + peak. It indicates
that 5 protons were eliminated from DTPA during the ionization process (Figure
4).
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Figure 4: MALDI-TOF spectrum of Doxo-S-S-Gd-DTPA prodrug.
Synthesis of activatable magnetic nanoprobe: After the preparation of IONPs
and Doxo-SS-Gd-DTPA solutions, the nanoprobe was formulated. Doxo-SS-GdDTPA complex was encapsulated into PAA coatings of IONPs, using solvent
diffusion technique. After the encapsulation, pure solution of IONP-PAA-DoxoSS-Gd-DTPA was obtained by dialysis technique and conjugation with folate was
carried out to achieve surface functionality. As most of the cancer cells have
folate receptor overexpression, folic acid was used as a targeting ligand for
prostate cancer. The functionalization was carried out using EDC/NHS bio
conjugation chemistry (Scheme 7). First, EDC solution was added to IONP-PAADoxo-SS-Gd-DTPA complex followed by addition of NHS and PEG-Folate.
Therefore, a solution of IONP-PAA-Doxo-SS-Gd-DTPA-Fol (nanoprobe) was
obtained and purified using dialysis. This solution was characterized and used for
performing experiments.
18

Characterization of Functional nanoprobe: Post encapsulation within IONPs
was characterized using UV/Vis and fluorescence measurement, which shows
peaks at 485 and 495, respectively. These values were similar to what we
observed prior to encapsulation, indicating that there is no major change in the
characteristics after encapsulating Doxo-SS-Gd-DTPA complex in the IONPs. To
check the magnetic property of the nanoprobe, we quantified MR signals which
were found to be 139 ms and 79 ms of T1 and T2 values individually (Table 1).
The reason for the change in T1 and T2 before and after encapsulation is
because this T1 MR activatable prodrug’s signal would be (Doxo-SS-Gd-DTPA)
quenched in presence of IONP (strong T2 agent). However, when the prodrug
enters the body a strong T1 signal could be noticeable only in the acidic
microenvironment of tumor where it gets activated.
Furthermore, the presence of folate on the surface after conjugation was
detected by UV Vis and fluorescence. The absorbance wavelength was abs =
365 nm and the fluorescence was em = 452 nm after surface conjugation with
folate (Figure 5D & B). The wavelength of absorbance and fluorescence
intensity were comparative to that of free folic acid depicting there is no change
in the characteristics of folate after conjugation. (Figure 5A & C).
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Scheme 7: Surface conjugation of Fol-PEG-NH2 on the IONPs using EDC/NHS
chemistry.

Figure 5: Surface conjugation with folate UV (A) Free folic acid, (B) Doxo-Fol.
Surface conjugation with folate Fluorescence (C) Free folic acid, (D) Doxo-Fol
fluorescence.
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Characterization studies: The hydrodynamic size and zeta potential of IONPCOOH, Doxo-SS-Gd-IONPs, and Doxo-SS-Gd-IONPs-Fol were determined with
the help of DLS. According to the results (Figure 6), the size of IONP-COOH was
noted to be 66.57 nm, while Doxo-SS-Gd-IONPs size was increased to 72.26 nm
due to its encapsulation. After folate conjugation on the surface of Doxo-SS-GdIONPs, the hydrodynamic diameter was amplified to 75.91 nm. Increase in size
portrays the presence of a huge functional group on the surface. Zeta potential of
the solutions was also determined along with the hydrodynamic diameter. The
surface zeta potential of IONP-COOH was noted to be -32.7 mV because of the
negativity of -COOH group. Whereas, the surface charge for Doxo-SS-Gd-IONPs
was determined to be -26.6 mV and that of nanoprobe conjugated with the folate
had a zeta potential of -38.4 mV. Hence, the change in zeta potential before and
after conjugation depicts the successful conjugation of folate on the surface of
IONP-COOH.

21

Figure 6: Determination of size and zeta potentials of the functional
nanoprobes.
In-vitro Cell viability (MTT assay): MTT assay is a colorimetric assay which
helps to find out the cytotoxicity of drug by determining the cell viability. In the
presence of mitochondrial reductase of healthy cells, MTT solution turns to
formazan crystals (purple colored compound). The yellow colored MTT solution
when added to the nanoprobe treated cells changes to purple color indicating the
cells viability. Depending on the density of the color, we could determine how

22

many cells are viable. In here, we used this cell based assay in determining the
cytotoxicity of IONP-Doxo-SS-Gd-DTPA probe on LNCaP cells. Different time
points were selected for conducting the experiment. Initially, we seeded the cells
in a 96 well plate and then treated them with different composition of nanoprobe
encapsulated in IONPs. As see in (Figure 7), after 24 h treatment, IONP-DoxoSS-Gd-DTPA-Fol show 60 % cell viability whereas IONP-Doxo-Fol have 70 %
cell viable. When relating this result with IONP-Gd-DTPA-Fol, it has 80% cells
viable showing minimal cytotoxic effect. The cytotoxicity study at 36 h displayed
the cell viability after treatment with IONP-Doxo-SS-Gd-DTPA-Fol was as low as
35% whereas with IONP-Doxo-Fol was approximately 40%, which was fairly
close to the cytotoxicity value of the former.

Figure 7: Cellular toxicity of the nanoprobe using LNCaP cells and PC3 cells.
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The cell viability after treating with IONP-Gd-DTPA remained pretty constant
proving that it does not play a major role in the cytotoxicity. At 48 h, treatment
with IONP-Doxo-SS-Gd-DTPA-Fol resulted in the viability to be least, suggesting
maximum cell death. Similar cytotoxicity was also observed with IONP-Doxo-Fol
while IONP-Gd-DTPA-Fol showed very low cytotoxicity. Conclusively, IONPDoxo-SS-Gd-DTPA-Fol probe was effective in killing the cancer cells over time.
As a negative control, the same assay was performed on PC-3 cells and the
viability of cells were found to be consistent at all-time points. This indicates that
the nanoprobe designed was specific to LNCaP cells.
Cell Internalization Studies: Following the MTT assay, the nanoprobes ability to
enter the cancerous cells were visually determined by performing cellular uptake
study. After 12 h of treatment with the nanoprobe (Figure 8A-D), we observed
cytoplasm was stained red due to the fluorescence effect of Doxo whereas the
nucleus was stained blue with DAPI dye suggesting the internalization of
nanoprobes into the LNCaP cells. As in Figure 8E-L, at 24 h and 48 h, the
amount of cell viability decreased drastically indicating the cytotoxic effect of
Doxo on LNCaP. When similar cell uptake study was done with PC-3 cells, there
was negligible entry of the nanoprobe proving the specificity of the nanoprobe to
LNCaP cells as in figure 8M-P.
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Figure 8: Cellular toxicity and viability of MR activatable nanoprobe.
We performed activation study at different pH for different concentration of Gd
encapsulated in nanoprobe at 0 h and 24 h. We can notice from Figure 9 that
increase in Gd concentration, Δ1/T1 value was increased and maximum T1 MR
activation was observed at pH 4.0-5.0. This also indicated that the signal is
directly proportional to the concentration and related to change in pH. Parallelly,
Δ1/T2 value was plotted for different concentration of Fe at different pH and
found that there was minimal change in T2 MR signal between these different
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groups. In conclusion, the synthesized nanoprobe was T1 MR activatable and
cytotoxic in vitro.

Figure 9: Evaluation of magnetic activation of Doxo-SS-Gd-DTPA-IONPs-Fol
using Bruker’s magnetic relaxometer.
MRI-Based T1-Weighted Activation of the Composite Nanoprobe: We
studied if the observed pH-dependent increases in R1 (1/T1) of the nanoprobe
results leads to increases in the T1-weighted signal in MRI, which leads to an
increase in the brightness of the image. This would be one-step closer to the
application of our nanoprobe for the cancer imaging application. For this, we took
the different concentrations of our prodrug encapsulating IONPs and used 9T
clinical MRI instrument for the T1 and T2 MR scanning at pH 5.0 (Figure 10).
26

The T1-weighted MR signals were increased as the concentrations of the
activatable nanoprobes increase (from 0.75 to 6.0 μM of Gd), which reflected in
the increase in T1 signals of the corresponding MR images (Figure 10A). This is
indicative of the T1 MR signal activation at the lower pH. However, the T2 MR
signal was not quenched, rather the images were darker as the iron
concentrations increased (Figure 10B).

Figure 10: Magnetic resonance imaging (MRI) studies measuring the T1 MR
activation in PBS, pH 5.0 using Bruker’s 9T clinical MRI instrument.
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CHAPTER III

METHODS AND EXPERIMENTAL SECTION
Synthesis of PAA coated IONPs: Iron oxide nanoparticles (IONPs) coated with
PAA were synthesized using “water-based precipitation method”. To synthesize
PAA coated IONPs, three solutions were prepared: i) Iron salts solution (0.7 g of
FeCl3.6 H2O and 0.4 g of FeCl2 .4H2O in 100 μL of 12 N HCl and 2 mL of DI H2O),
ii) an alkaline solution (1.8 mL of 30% NH4OH solution in 15 mL of deionized water)
and iii) stabilizing agent solution (2 g of PAA in 5 mL of DI water). The synthetic
procedure was as follows: The solution of iron salts was added into alkaline
solution. Afterwards, stabilizing agent (PAA in DI water) was added to the above
solution and the reaction was continued at a speed of 4000 rpm. Then, the resulting
IONPs were centrifuged at 3000 rpm, 4000 rpm and 4000 rpm for 20 min each,
respectively. The supernatant obtained after the final centrifugation was dialyzed
in a dialysis bag, which has a molecular weight cut off range of 6-8 kDa. The
dialysis process was done in beaker with DI water and a magnetic stirrer. The water
was changed periodically for 24 h and the dialyzed IONPs were taken out of
dialysis bag, labelled and stored.
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Synthesis of the Gd-DTPA: Gd-DTPA is a highly stable paramagnetic complex
which was synthesized by adding a solution of gadolinium chloride hexahydrate
(GdCl3.6H2O) in a solution of diethylenetriaminepentaacetic acid (DTPA). 4.49 g
of GdCl3.6H2O was dissolved in 10 mL of deionized water to make a molar
concentration of 0.0121 M. Then, DTPA of 5.0 g was dissolved in 30 mL of water
containing 2 N NaOH (5.0 mL) solution to form 0.0127 M solution of DTPA. These
prepared stock solutions of gadolinium and DTPA were mixed together by
dropwise addition of GdCl3.6H2O solution to DTPA solution. Thereafter, 2 N NaOH
was continuously added to the above solution to bring the pH to 6.8 and the
reaction was maintained at 80C for 12 h. This reaction led to the formation of
white crystals which were initially dissolved little amount of water followed by
precipitation with ethanol. Once precipitated the solution was filtered to remove the
Gd-DTPA complex and dried under vacuum
Encapsulation of Gd-DTPA-IONPs: In a 15 mL tube, we took 5 mL of the freshly
prepared IONP and then we added 500 μL of Gd-DTPA drop by drop at 1200 rpm
on vortex mixer. It was allowed to mix in the orbital mixer overnight and then T1
and T2 values were detected.
Synthesis of Doxo-SS-Gd-DTPA: Doxorubicin hydrochloride salt was made into
an aqueous solution and added to PBS buffer solution of pH 7.4 to form amine free
doxorubicin. This was allowed to centrifuge and the supernanant was removed.
The solid pellet from the centrifugate was dissolved in dimethyl sulfoxide (DMSO)
forming doxorubicin solution. 1.84 mM solution of dithiobis (succinimidyl
propionate) (DSP) was added dropwise to a mixture containing solution of Gd-
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DTPA complex solution and doxorubicin solutions. To this above mixture, a small
amount of triethylamine (0.4 μL in DMSO) was added at 25C for 30 mins, followed
by incubation overnight at 4C. The synthesized probe was finally characterized
using various spectroscopic methods including MALDI-TOF.
MALDI Matrix Preparation:
1. Preparation of TA30 Solvent:
TA30 is a 30:70 (vol/vol) mixture of acetonitrile (ACN): trifluoroacetic acid
(TFA) in deionized water. First, the acid solution was diluted, then
combined with 300 μL AcN + 699.3 μL deionized water + 0.7 μL TFA = 1
mL TA30.
2. Matrix Solubilization:
Add 2, 5-Dihydroxybenzoic acid (20 mg/mL) to the TA3O solution and
vortex until dissolved.
3. Sample Preparation:
Nanoprobe was dissolved in methanol of 50 mg/mL.
4. Sample Plating:
Equal volumes of matrix solution and nanoprobe solution were taken into
a new tube and vortexed for a few minutes until thoroughly mixed. Then,
0.5 μL drop of this solution was placed on the MALDI plate. The sample
was allowed to completely air dry in the hood overnight.
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Cytotoxicity assay (MTT): For estimating the toxicity of the nanoprobe, MTT
assay was performed. LNCaP cells were seeded on a 96 well plate for 24 hours
and stored at 37°C. On the next day, they were treated with IONP-Gd-Fol, IONPDOXO-Fol and IONP-Doxo-SS-Gd-DTPA-Fol, which was incubated for 12, 24,
36 and 48 hours. Following the respective treatment period, 30 μL MTT solution
was added in each well and again stored for 4-6 hours. This helped in formation
of purple formazan crystals which could help us in determining the live cells. To
dissolve the purple color formazan, acidic isopropyl solution was added and kept
on thermo-mixture overnight. Finally the fluorescence was measured at 570 nm
using a plate reader and results were plotted.

Magnetic relaxation: Magnetic relaxation of different samples were performed
at KUMC and images were obtained.
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CHAPTER IV

CONCLUSION

We designed and synthesized an activatable doxorubicin-based prodrug Doxo-SS-Gd-DTPA and characterized it using various spectroscopic methods. This
prodrug was encapsulated in PAA-coated IONPs and characterized. The IONPPAA-Doxo-SS-Gd-DTPA-Fol nanoprobe, which quenches T1 signal (low ∆1/T1),
when at close vicinity to the strong T2 agent IONP. Upon release of Doxo-SSGd-DTPA from the nanoprobe complex, ∆1/T1 was increased indicating
quenching effect. This release of the T1 agent from the IONP-based nanoprobe
complex leads to improved MRI contrast. Though the release of the Doxo-SSGd-DTPA altered T1 signal, it had only minimal effect on T2 signaling.
Next, we performed cell uptake study in order to assess the specificity of the
nanoprobe to the LNCaP cells, which targeted only cancerous cells because of
the functionalization with folate on the IONPs. Once internalized, the nanoprobe
complex was dissociated due to the presence of glutathione, where Doxocomplex enhanced cytotoxic effect and Gadolinium-complex was helpful in MR
imaging. To assess the cytotoxic capability of the nanoprobe MTT assay was
performed, which showed that after nanoprobe treatment less viable cells were
present at 48 h. The activation study was performed which presented that the
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activation of nanoprobe varied with concentration and pH, showing maximum
activation taking place at relatively higher concentration and lower pH.
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